Further studies are needed to determine whether inhibition of AIF-mortalin interaction, dissociation of AIF from the OMM, and subsequent apoptosis can potentially turn into a therapeutic strategy in cancer cells with high levels of mortalin, such as glioma patients. This evidence concerns the gene AIFM1 and cancer.